Electroconvulsive therapy as a potentially effective treatment for severe serotonin syndrome: Two case reports

Journal of Clinical Psychopharmacology

Volumn 30, Issue 3, 2010, Pages 350-352

  Okamoto, Nagahisa ^a   Sakamoto, Kota ^a   Nagafusa, Yuko ^a   Ichikawa, Makoto ^a   Nakai, Tetsuji ^a   Higuchi, Teruhiko ^a  

^a National Center Hospital of Neurology and Psychiatry   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; ALANINE AMINOTRANSFERASE; AMITRIPTYLINE; AMOXAPINE; ATROPINE; C REACTIVE PROTEIN; CLOMIPRAMINE; DIAZEPAM; HOMOVANILLIC ACID; MIANSERIN; MIDAZOLAM; MILNACIPRAN; PAROXETINE; PROPOFOL; SERTRALINE; SULPIRIDE; SUXAMETHONIUM; UREA;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; AUDITORY HALLUCINATION; CASE REPORT; CATALEPSY; CATATONIA; CONFUSION; CONTINUOUS INFUSION; DELUSION; DEPRESSION; DIARRHEA; DISORIENTATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DYSPNEA; ELECTROCONVULSIVE THERAPY; FEVER; HALLUCINATION; HOT FLUSH; HUMAN; HYPERTENSION; HYPERTHERMIA; LETTER; LEUKOCYTOSIS; MAJOR DEPRESSION; MALE; MUSCLE RIGIDITY; MYOCLONUS; PARENTERAL NUTRITION; PRIORITY JOURNAL; SEROTONIN SYNDROME; SIDE EFFECT; SWEATING; TACHYCARDIA; TENDON REFLEX; TREMOR; UREA NITROGEN BLOOD LEVEL; VISUAL HALLUCINATION;

AGED; ANTIDEPRESSIVE AGENTS; ELECTROCONVULSIVE THERAPY; HUMANS; MALE; SEROTONIN SYNDROME; TREATMENT OUTCOME;

EID: 77952327455     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181df6130     Document Type: Letter

References (14)

1. Hegerl U, Bottlender R, Gallinat J, et al. The serotonin syndrome scale: first results on validity. Eur Arch Psychiatry Clin Neurosci. 1998;248:96-103.
2. Fink M, Taylor MA. The catatonia syndrome: forgotten but not gone. Arch Gen Psychiatry. 2009;66:1173-1177.
3. Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148:705-713.
4. Radomski JW, Dursun SM, Reveley MA, et al. An exploratory approach to the serotonin syndrome: an update of clinical phenomenology and revised diagnostic criteria. Med Hypotheses. 2000;55:218-224.
5. Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatry. 1985;142: 1137-1145.
6. Lane R, Baldwin D. Selective serotonin reuptake inhibitorYinduced serotonin syndrome: review. J Clin Psychopharmacol. 1997;17:208-221.
7. Ochiai Y, Katsu H, Okino S, et al. Case of prolonged recovery from serotonin syndrome caused by paroxetine. Seishin Shinkeigaku Zasshi. 2003;105: 1532-1538.
8. Insel TR, Roy BF, Cohen RM, et al. Possible development of the serotonin syndrome in man. Am J Psychiatry. 1982;139:954-955.
9. Trollor JN, Sachdev PS. Electroconvulsive treatment of neuroleptic malignant syndrome: a review and report of cases. J Clin Psychopharmacol. 2000;20:257-259.
10. Mann SC, Auriacombe M, Macfadden W, et al. Lethal catatonia: clinical aspects and therapeutic intervention. A review of the literature. Encephale. 2001;27:213-216.
11. Fink M. Toxic serotonin syndrome or neuroleptic malignant syndrome? Pharmacopsychiatry. 1996;29:159-161. (Pubitemid 26247567)
12. Nisijima K, Nibuya M, Kato S. Toxic serotonin syndrome successfully treated with electroconvulsive therapy. J Clin Psychopharmacol. 2002;22:338-339.
13. Sartorius A, Wolf J, Henn FA. Lithium and ECTVconcurrent use still demands attention: three case reports. World J Biol Psychiatry. 2005;6:121Y124.
14. Nisijima K, Nibuya M, Sugiyama H. Abnormal CSF monoamine metabolism in serotonin syndrome. J Clin Psychopharmacol. 2003;23:528Y531.